Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1
Author(s):
Mease, P.J.; Heijde, D. van der; Ritchlin, C.T.; Okada, M.; Cuchacovich, R.S.; Shuler, C.L.; Lin, C.Y.; Braun, D.K.; Lee, C.H.; Gladman, D.D.; SPIRIT-P1Study Grp
Published
2017
Publication type
Article / Letter to editor
Date issued
2017-01-31
Language
English
Is part of
Annals of the Rheumatic Diseases (2017), Vol. 76, no. 1, p. 79-87
